Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -128.96% is in line with its 5-year average of -129.28%, around the middle of its 5-year range (-218.99%–-86.04%).
1.15% below its 12-month average of -127.49%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -36.14%.
RETURN ON ASSETS (ROA)
-128.96%
RETURN ON ASSETS (ROA) AVG TTM
-127.49%
RETURN ON ASSETS (ROA) AVG 3Y
-112.64%
RETURN ON ASSETS (ROA) AVG 5Y
-129.28%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.15%
CURRENT VS 3Y AVG
-14.49%
CURRENT VS 5Y AVG
+0.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-300.00%
vs the sector median at left
Genelux Corporation
Market Cap
$113.89M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$114.08M
Return on Assets (ROA)
-19.30%
TTM Avg
-19.59%
3Y Avg
-15.38%
5Y Avg
-15.18%
Market Cap
$113.61M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$114.24M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$114.84M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
Market Cap
$112.57M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$111.33M
Return on Assets (ROA)
-48.90%
TTM Avg
-85.01%
3Y Avg
-256.52%
5Y Avg
-384.82%
Market Cap
$109.79M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$119.17M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $113.89M | -128.96% | -127.49% | -112.64% | -129.28% |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -19.30% | -19.59% | -15.38% | -15.18% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.61M | -31.75% | -34.00% | -32.33% | -29.29% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.24M | -0.05% | -38.03% | -60.31% | -59.32% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.84M | -134.18% | -145.83% | -164.39% | -180.40% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -72.42% | -66.03% | -45.57% | -48.77% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $111.33M | -48.90% | -85.01% | -256.52% | -384.82% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.79M | -167.64% | -183.95% | -119.46% | -95.34% |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.17M | -49.93% | -95.40% | -72.70% | -57.07% |
| Apyx Medical Corporation (APYX)vs › | $108.01M | -14.14% | -26.48% | -30.34% | -26.58% |
ROA
-129.0%
ROE
-209.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -168.94% |
| 2024-12-31 | -86.04% |
| 2023-12-31 | -101.45% |
| 2022-12-31 | -94.14% |
| 2021-12-31 | -218.99% |
| 2020-12-31 | -106.11% |
| 2019-12-31 | -354.50% |
